🇺🇸 FDA
Pipeline program

ALX1-11 50 mcg

CL1-11-821

Phase 2 small_molecule completed

Quick answer

ALX1-11 50 mcg for Osteoporosis is a Phase 2 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda Pharmaceuticals International AG
Indication
Osteoporosis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials